DOCSLIB.ORG

Disease Considered As Candidates for Global Eradication By

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Disease Considered As Candidates for Global Eradication By Disease considered as candidates for global eradication by the International Task Force for Disease Eradication1 Current annual toll Disease worldwide Chief obstacles to eradication Conclusion Diseases targeted for eradication Dracunculiasis <10,000 persons infected; Sporadic insecurity Eradicable (Guinea worm disease) few deaths WHA 44.5 (1991) Lymphatic filariasis 120 million cases Weakness of primary health care systems Potentially eradicable in Africa; increased national/international WHA 50.29 (1997) commitment needed Measles 780,000 deaths, mostly Lack of suitably effective vaccine for Potentially eradicable among children young infants; cost; public misconception of seriousness Mumps Unknown Lack of data on impact in developing Potentially eradicable countries; difficult diagnosis Poliomyelitis 2,000 cases of paralytic Insecurity; low vaccine coverage; Eradicable disease; 200 deaths increased national commitment needed WHA 41.28 (1988) Rubella Unknown Lack of data on impact in developing Potentially eradicable countries; difficult diagnosis Taeniasis/cysticercosis 50 million cases; 50,000 Demonstration of elimination on national Potentially eradicable (pork tapeworm) deaths scale Diseases/conditions of which some aspects could be eliminated American trypanosomiasis 10—12 million infected Difficult diagnosis, treatment; animal Not eradicable; can stop (Chagas’ disease) reservoirs vector-borne transmission to humans in some areas Hepatitis B 250,000 deaths Carrier state, infections in utero not Not now eradicable, but preventable; need routine infant could eliminate vaccination transmission over several decades Iodine deficiency disorders Unknown Inadequate surveillance, lack of Could eliminate iodine environmental sources of iodine deficiency disorders Malaria >300 million cases; >1 National and international commitment, Not now eradicable; million deaths weak primary health care systems; drug elimination possible in and insecticide resistance; non-specific Hispaniola diagnoses Neonatal tetanus 560,000 deaths Inexhaustible environmental reservoir Not now eradicable, but could prevent transmission Onchocerciasis 37—40 million cases; Lack of macrofilaricide and test for living Could eliminate (river blindness) 340,000 blind adult worms associated blindness in Africa; and probably transmission in the Americas Rabies 52,000 deaths No effective way to deliver vaccine to Could eliminate urban wild animals that carry the disease rabies Trachoma 150 million cases; Link to poverty; inadequate rapid Could eliminate 6 million blind assessment methodology and diagnostic associated blindness test for ocular infection WHA 51.11 (1998) 1 (Updated April 2008) CDC. Recommendations of the International Task Force for Disease Eradication. Morbidity and Mortality Weekly Report 1993; 42(RR-16):8. This report and summaries from ITFDE (II) meetings can be found at www.cartercenter.org. Yaws and other endemic Unknown Lack of political will, inadequate Could eliminate treponematoses funding, weaknesses in primary health transmission nationwide, care systems as shown by India* Diseases that are not eradicable now Ascariasis (roundworm) 1 billion infected; 20,000 Eggs viable in soil for years; laborious Not now eradicable deaths diagnosis; widespread Cholera Unknown Environmental reservoirs; strain Not now eradicable differences Diphtheria Unknown Difficult diagnosis; multiple-dose Not now eradicable vaccine Hookworm disease 740 million cases; 10,000 Increased national and international Not now eradicable deaths commitment; monitoring impact of interventions Leprosy (Hansen’s disease) 225,000 cases Need for improved diagnostic tests and Not now eradicable chemotherapy; social stigma; potential reservoir in armadillos Meningococcal meningitis 614,000 cases; 180,000 Lack of serogroup A conjugate vaccine; Not now eradicable deaths cost Pertussis 40 million cases; 400,000 High infectiousness; early infections; Not now eradicable (whooping cough) deaths multiple-dose vaccine Rotaviral enteritis 80 million cases; 870,000 Inadequate vaccine Not now eradicable deaths Schistosomiasis 200 million infected Reservoir hosts; increased snail- Not now eradicable (bilharziasis) breeding sites; need simple diagnostic test for intestinal disease Tuberculosis 8–10 million new cases; 2– Need for improved diagnostic tests, Not now eradicable 3 million deaths chemotherapy and vaccine; wider application of current therapy Visceral leishmaniasis 500,000 cases Inadequate surveillance, drug supply and Not now eradicable knowledge of vector breeding sites; weak primary health care systems Yellow fever >10,000 deaths Sylvatic reservoir; heat-labile vaccine Not now eradicable Diseases that are not eradicable African trypanosomiasis 300,000—600,000 infected Reservoir hosts; difficult treatment and Not eradicable diagnosis Amebiasis 500 million cases; Asymptomatic infections; difficult Not eradicable 40,000—110,000 deaths diagnosis, treatment Bartonellosis Unknown Asymptomatic infections; difficult Not eradicable diagnosis, treatment Buruli ulcer Unknown Inadequate surveillance, early detection Not eradicable and treatment; need field diagnostic test and orally administered treatment Clonorchiasis 20 million cases in China Animal reservoir; asymptomatic Not eradicable alone infections; carrier state Enterobiasis Unknown Widespread; mild disease Not eradicable Varicella zoster 3 million cases in USA Latency of virus; inadequate vaccine Not eradicable alone *Because persons may be infected for decades and the organisms cannot be distinguished from those that cause venereal syphilis, elimination of transmission–not eradication–is the goal. .
Load more

Recommended publications
  • Dolo Et Al., 2020
    Serological Evaluation of Onchocerciasis and Lymphatic Filariasis Elimination in the Bakoye and Falémé foci, Mali Housseini Dolo1,6*, Yaya I. Coulibaly1,2, Moussa Sow3, Massitan Dembélé4, Salif S. Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciaa318/5811165 by guest on 29 April 2020 Doumbia1, Siaka Y. Coulibaly1, Moussa B. Sangare1, Ilo Dicko1, Abdallah A. Diallo1, Lamine Soumaoro1, Michel E. Coulibaly1, Dansine Diarra5, Robert Colebunders6, Thomas B. Nutman7, Martin Walker8*, Maria-Gloria Basáñez9* 1 Lymphatic Filariasis Research Unit, International Center of Excellence in Research, Faculty of Medicine and Odontostomatology, Point G, Bamako, Mali 2 Centre National d’Appui à la lutte contre la Maladie (CNAM), Bamako, Mali 3 Programme National de Lutte contre l’Onchocercose, Bamako, Mali 4 Programme National d’Elimination de la Filariose Lymphatique, Bamako, Mali 5 Faculty of Geography and History, Bamako, Mali 6 Global Health Institute, University of Antwerp, Antwerp, Belgium 7 Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA 8 Department of Pathobiology and Population Sciences and London Centre for Neglected Tropical Disease Research, Royal Veterinary College, Hatfield, UK 9 Department of Infectious Disease Epidemiology and London Centre for Neglected Tropical Disease Research, MRC Centre for Global Infectious Disease Analysis, Imperial College London, UK * contributed equally to this work. Correspondence
    [Show full text]
  • CDC Center for Global Health 2016 Annual Report
    CDC CENTER FOR GLOBAL HEALTH (CGH) 2016 ANNUAL REPORT Photo Credit: Athit Perawongmtha Photo Credit: Ashley Greiner 2016 CENTER FOR GLOBAL HEALTH (CGH) ANNUAL REPORT Message from the Director CDC’s global health work has a clear mission: to protect and improve health globally through science, policy, partnership, and evidence- based public health action. By ensuring that countries have the capabilities to prevent, detect, and respond to or treat health threats within their borders, the Center for Global Health (CGH) helps prevent regional and global health crises that affect health, security, and economic stability abroad and at home. Rebecca Martin In 2016, CGH’s dedicated staff advanced this mission across many Director, Center for Global Health, disease goals and geographic areas around the world. This annual Centers for Disease Control report illustrates the work that has been done in 2016 and provides and Prevention a portrait of CGH’s priorities and achievements, and the work that remains. This report also illustrates why CDC’s global health work is important and how it contributes to protecting people’s health and quality of life, both in the United States and abroad. I am proud of the strategic and impactful work in CGH over the last year, often under difficult and challenging conditions. This report highlights how scientists, epidemiologists, laboratory specialists, and countless other highly-trained experts from CGH were instrumental in achieving immunization of children at risk, in pressing forward in the fight against HIV and tuberculosis (TB), and in leading the efforts to control malaria, Zika, and a collection of other dangerous diseases that still afflict far too many people.
    [Show full text]
  • How Should Indonesia Consider Its Neglected Tropical Diseases in the COVID-19 Era? Hopes and Challenges (Review)
    BIOMEDICAL REPORTS 14: 53, 2021 How should Indonesia consider its neglected tropical diseases in the COVID-19 era? Hopes and challenges (Review) SHIFA FAUZIYAH1, SERIUS MILIYANI DWI PUTRI1, ZUKHAILA SALMA1, HAMIDAH RETNO WARDHANI1, FARADILA KHOIRUN NISA' HAKIM1, TEGUH HARI SUCIPTO2, FEBRIANA AQUARESTA3,4 and SOEGENG SOEGIJANTO2,5 1Master Program of Tropical Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java 60132; 2Dengue Study Group, Institute of Tropical Disease, Universitas Airlangga, Surabaya, East Java 60115; 3Clinical Microbiology Specialist Program, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java 60132; 4Palembang Health Laboratory Center, Palembang, South Sumatra 30126; 5Department of Pediatric, Faculty of Medicine, Universitas Wijaya Kusuma Surabaya, Surabaya, East Java 60225, Indonesia Received December 3, 2020; Accepted March 24, 2021 DOI: 10.3892/br.2021.1429 Abstract. During the coronavirus disease 2019 (COVID‑19) Government‑supported integrated management is also a key pandemic, some countries, including Indonesia, have faced a component in eliminating NTD. Moreover, healthy lifestyle double burden with regards to disease control. As Indonesia campaigns that include social distancing, wearing a mask and is a tropical country, it serves as a suitable host for disease regularly washing hands should be promoted continuously to vectors and multiple microorganisms of causative agents of reduce the transmission of COVID‑19, which is potentially disease. In total, five of the neglected tropical diseases (NTDs) associated with a poor outcome in individuals with NTDs. should be a consideration in Indonesia during the COVID‑19 This review concluded that the Indonesian government should pandemic, including leprosy, yaws, filariasis, soil‑trans‑ strengthen their efforts toward NTD control using alternative mitted helminths and schistosomiasis.
    [Show full text]
  • Disseminated Peritoneal Schistosoma Japonicum: a Case Report And
    [Downloaded free from http://www.saudiannals.net on Monday, May 10, 2010] case report Disseminated peritoneal Schistosoma japonicum: a case report and review of the pathological manifestations of the helminth Salah Al-Waheeb,a Maryam Al-Murshed,a Fareeda Dashti,b Parsotam R. Hira,c Lamia Al-Sarrafd From the aDepartments of Histopathology, and bSurgery, Mubarak Al-Kabeer Hospital, cDepartment of Microbiology, Kuwait University, dDepart- ment of Radiology, Mubarak Al-Kabeer Hospital, Jabriyah, Kuwait Correspondence: Salah Al-Waheeb, MD · Mubarak Al-Kabeer Hospital, PO Box 72, Code 71661, Jabriyah, Shamiyah City, Kuwait · T: +975-531- 2700 ext. 2188 · [email protected] · Approved for publication August 2008 Ann Saudi Med 2009; 29(2): 149-152 Schistosomiasis (also known as bilharzia, bilharziasis, bilharziosis or snail fever) is a human disease syn- drome caused by infection from one of several species of parasitic trematodes of the genus Schistosoma. The three main species infecting humans are S haematobium, S japonicum, and S mansoni. S japonicum is most common in the far east, mostly in China and the Philippines. We present an unusual case of S japonicum in a 32-year-old Filipino woman who had schistosomal ova studding the peritoneal cavity and forming a mass in the right iliac fossa. chistosomiasis (also known as bilharzia, bilharziaa liver (Figure 1). CT examination showed multiple cala asis, bilharziosis or snail fever) is a human disease cific foci throughout the abdomen, particularly in the Ssyndrome caused by infection from one of several RIF. Prominent small bowel dilatation and fluid colleca species of parasitic trematodes of the genus Schistosoma.
    [Show full text]
  • Ultrasound of Tropical Medicine Parasitic Diseases of the Liver
    Ultrasound of the liver …. 20.11.2012 11:05 1 EFSUMB – European Course Book Editor: Christoph F. Dietrich Ultrasound of Tropical Medicine Parasitic diseases of the liver Enrico Brunetti1, Tom Heller2, Francesca Tamarozzi3, Adnan Kabaalioglu4, Maria Teresa Giordani5, Joachim Richter6, Roberto Chiavaroli7, Sam Goblirsch8, Carmen Cretu9, Christoph F Dietrich10 1 Department of Infectious Diseases, San Matteo Hospital Foundation- University of Pavia, Pavia, Italy 2 Department of Internal Medicine, Klinikum Muenchen Perlach, Munich, Germany 3 Department of Infectious Diseases, San Matteo Hospital Foundation- University of Pavia, Pavia, Italy 4 Department of Radiology, Akdeniz University, Antalya, Turkey 5 Infectious and Tropical Diseases Unit, San Bortolo Hospital, Vicenza, Italy 6 Tropenmedizinische Ambulanz, Klinik für Gastroenterologie, Hepatologie und Infektiologie, Heinrich-Heine-Universität, Düsseldorf, Germany 7 Infectious Diseases Unit, Santa Caterina Novella Hospital, Galatina, Italy 8 Department of Medicine and Pediatrics, University of Minnesota, Minneapolis, MN, USA 9 University of Medicine and Pharmacy "Carol Davila" Parasitology Department Colentina Teaching Hospital, Bucharest, Romania 10 Caritas-Krankenhaus Bad Mergentheim, Germany Ultrasound of parasitic disease …. 20.11.2012 11:05 2 Content Content ....................................................................................................................................... 2 Amoebiasis ................................................................................................................................
    [Show full text]
  • Eisai Announces Results and Continued Support Of
    No.17-18 April 19, 2017 Eisai Co., Ltd. EISAI ANNOUNCES RESULTS AND CONTINUED SUPPORT OF INITIATIVES FOR ELIMINATION OF LYMPHATIC FILARIASIS 5 YEAR ANNIVERSARY OF LONDON DECLARATION ON NEGLECTED TROPICAL DISEASES Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) has announced the results of its initiatives for the elimination of lymphatic filariasis (LF), and its continued support of this cause in the future. This announcement was made at an event held in Geneva, Switzerland, on April 18, marking the 5th anniversary of the London Declaration on Neglected Tropical Diseases (NTDs), an international public-private partnership. Announced in January 2012, the London Declaration is the largest public-private partnership in the field of global health, and represents a coordinated effort by global pharmaceutical companies, the Bill & Melinda Gates Foundation, the World Health Organization (WHO), the United States, United Kingdom and NTD-endemic country governments, as well as other partners, to eliminate 10 NTDs by the year 2020. Since the signing of the London Declaration, donations of medical treatments by pharmaceutical companies have increased by 70 percent, and these treatments contribute to the prevention and cure of disease in approximately 1 billion people every year. Under the London Declaration, Eisai signed an agreement with WHO to supply 2.2 billion high-quality diethylcarbamazine (DEC) tablets, which were running in short supply worldwide, at Price Zero (free of charge) by the year 2020. These DEC tablets are manufactured at Eisai’s Vizag Plant in India. As of the end of March 2017, 1 billion tablets have been supplied to 27 endemic countries.
    [Show full text]
  • Biliary Obstruction Caused by the Liver Fluke, Fasciola Hepatica
    CME Practice CMAJ Cases Biliary obstruction caused by the liver fluke, Fasciola hepatica Takuya Ishikawa MD PhD, Vanessa Meier-Stephenson MD PhD, Steven J. Heitman MD MSc Competing interests: None 20-year-old previously healthy man declared. presented to hospital with a two-day This article has been peer A history of right upper quadrant pain reviewed. and vomiting. Nine months earlier, he had The authors have obtained immigrated to Canada from Sudan, but he had patient consent. also lived in Djibouti and Ethiopia. Four Correspondence to: months before he presented to hospital, he Steven Heitman, received a diagnosis of tuberculous lymphade- [email protected] nitis and a four-drug course of tuberculosis CMAJ 2016. DOI:10.1503 treatment was started. However, he was non- /cmaj.150696 adherent after only two months of treatment. In addition, results from screening tests at that time showed evidence of schistosomiasis for Figure 1: A flat, leaf-shaped, brown worm emerg- which he was prescribed praziquantel. ing from the common bile duct of a 20-year-old On examination, he was alert and without man with abdominal pain. jaundice or scleral icterus. He had right upper quadrant tenderness on abdominal examination, ter of 1.1 cm. A computed tomography scan of but there were no palpable masses. The remain- the abdomen also showed prominence of the der of his examination was unremarkable. Labo- common bile duct, but no calcified stone was ratory test results showed elevated liver enzymes identified (Appendix 1). A hepatobiliary imino- (aspartate transaminase 133 [normal < 40] U/L, diacetic acid scan suggested distal obstruction in alanine transaminase 217 [normal < 41] U/L, the common bile duct.
    [Show full text]
  • Imaging Parasitic Diseases
    Insights Imaging (2017) 8:101–125 DOI 10.1007/s13244-016-0525-2 REVIEW Unexpected hosts: imaging parasitic diseases Pablo Rodríguez Carnero1 & Paula Hernández Mateo2 & Susana Martín-Garre2 & Ángela García Pérez3 & Lourdes del Campo1 Received: 8 June 2016 /Revised: 8 September 2016 /Accepted: 28 September 2016 /Published online: 23 November 2016 # The Author(s) 2016. This article is published with open access at Springerlink.com Abstract Radiologists seldom encounter parasitic dis- • Some parasitic diseases are still endemic in certain regions eases in their daily practice in most of Europe, although in Europe. the incidence of these diseases is increasing due to mi- • Parasitic diseases can have complex life cycles often involv- gration and tourism from/to endemic areas. Moreover, ing different hosts. some parasitic diseases are still endemic in certain • Prompt diagnosis and treatment is essential for patient man- European regions, and immunocompromised individuals agement in parasitic diseases. also pose a higher risk of developing these conditions. • Radiologists should be able to recognise and suspect the This article reviews and summarises the imaging find- most relevant parasitic diseases. ings of some of the most important and frequent human parasitic diseases, including information about the para- Keywords Parasitic diseases . Radiology . Ultrasound . site’s life cycle, pathophysiology, clinical findings, diag- Multidetector computed tomography . Magnetic resonance nosis, and treatment. We include malaria, amoebiasis, imaging toxoplasmosis, trypanosomiasis, leishmaniasis, echino- coccosis, cysticercosis, clonorchiasis, schistosomiasis, fascioliasis, ascariasis, anisakiasis, dracunculiasis, and Introduction strongyloidiasis. The aim of this review is to help radi- ologists when dealing with these diseases or in cases Parasites are organisms that live in another organism at the where they are suspected.
    [Show full text]
  • Historical Dermatology & Vaccines
    9/24/2019 Historical Dermatology & Vaccines GREG SIMPSON MD Disclosures I do not have any relevant financial endorsements to disclose. I will be talking about the off label use of many medications UCSF Fresno Mini Med School 2019 1 9/24/2019 Outline History of select Infectious disease Infectious Disease and Vaccines Why the caduceus? UCSF Fresno Mini Med School 2019 2 9/24/2019 Case 1- 42 y.o. African male Dracunculiasis Guinea Worm Cyclops water flea in drinking water (carry the larvae) 1980’s- 3.5 million cases, 2018- 28 As of February 2019, only 7 countries remaining to be certified Guinea worm free: Angola, Chad, Democratic Republic of the Congo, Ethiopia, Mali, South Sudan, and Sudan Metronidazole or thiabendazole and stick Clean water sources, Larvicide (ABATE) or filters UCSF Fresno Mini Med School 2019 3 9/24/2019 CDC eradication program ERADICATED 1. Small Pox 2. Rinderpest GLOBAL ERADICATION UNDERWAY 1. Polio 2. Dracunculiasis 3. Yaws 4. Malaria REGIONAL ELIMINATION ESTABLISHED OR UNDERWAY 1. Hookworm 2. Lymphatic filariasis 3. Measles 4. Rubella 5. Onchocerciasis 6. Bovine spongiform encephalopathy (CJD) 7. Syphilis 8. Rabies Medical Significance? Asklepios- Greek God of medicine (1200 BC) Hippocrates 20th generation “follower” Today’s medical significance? Caduceus- Hermes (Greek) staff 1902- US Army and pharmacies used it as a “stamp” on medical supplies UCSF Fresno Mini Med School 2019 4 9/24/2019 The Black Death is estimated to have killed 30% to 60% of Europe’s population. In total, the plague may have reduced the world population from an estimated 450 million to 350–375 million in the 14th century.
    [Show full text]
  • TCM Diagnostics Applied to Parasite-Related Disease
    TCM Diagnostics Applied to Parasite-Related Disease by Laraine Crampton, M.A.T.C.M., L. Ac. Capstone Advisor: Lawrence J. Ryan, Ph.D. Presented in partial fulfillment of the requirements for the degree Doctor of Acupuncture and Oriental Medicine Yo San University of Traditional Chinese Medicine Los Angeles, California April 2014 TCM and Parasites/Crampton 2 Approval Signatures Page This Capstone Project has been reviewed and approved by: April 30th, 2014 ____________________________________________________________________________ Lawrence J. Ryan, Ph. D. Capstone Project Advisor Date April 30th, 2014 ________________________________________________________________________ Don Lee, L. Ac. Specialty Chair Date April 30th, 2014 ________________________________________________________________________ Andrea Murchison, D.A.O.M., L.Ac. Program Director Date TCM and Parasites/Crampton 3 Abstract Complex, chronic disease affects millions in the United States, imposing a significant cost to the affected individuals and the productivity and economic realities those individuals and their families, workplaces and communities face. There is increasing evidence leading towards the probability that overlooked and undiagnosed parasitic disease is a causal, contributing, or co- existent factor for many of those afflicted by chronic disease. Yet, frustratingly, inadequate diagnostic methods and clever adaptive mechanisms in parasitic organisms mean that even when physicians are looking for parasites, they may not find what is there to be found. Examining the practice of medicine in the United States just over a century ago reveals that fully a third of diagnostic and treatment concerns for leading doctors of the time revolved around parasitic organisms and related disease, and that the population they served was largely located in rural areas. By the year 2000, more than four-fifths of the population had migrated to cities, enjoying the benefits of municipal services, water treatment systems, grocery stores and restaurants.
    [Show full text]
  • The Global Elimination of Lymphatic Filariasis the Story of Zanzibar
    The Global Elimination of Lymphatic Filariasis The Story of Zanzibar WHO/CDS/CPE/SMT/2002.15 ACKNOWLEDGEMENTS The lymphatic filariasis (LF) elimination programme in Zanzibar is the story of the hard work and commitment, primarily of the people of Zanzibar. This document is an attempt to portray the dedication of the many people who were convinced of the importance of the LF programme and made the campaign a success. WHO is indebted to those who are mentioned within the pages of this publication, and also those not mentioned who nevertheless saw a vital role for themselves in making a difference to the health of their communities. This publication has been made possible by a contribution from the Bill and Melinda Gates Foundation. © World Health Organization 2002 This document is not a formal publication of the World Health Organization (WHO), and all rights are reserved by the Organization. The document may, however, be freely reviewed, abstracted, reproduced or translated, in part or in whole, but not for sale or for use in conjunction with commercial purposes. The views expressed in documents by named authors are solely the responsibility of those authors. The Global Elimination of Lymphatic Filariasis The Story of Zanzibar WORLD HEALTH ORGANIZATION WHO Tanzania Country Office WHO AFRO Regional Support WHO HQ Social Mobilization Team (CPE/SMT) WHO HQ Country Technical Support Team (CPE/CEE) Contents Letter from the WHO LF Support Team (HQ) 4 Lymphatic filariasis and the strategy for its elimination 6 Living with lymphatic filariasis 8 The partnership 9 Zanzibar profile 11 What is the value of eliminating LF? 12 The plan 14 The cost/value calculation 16 Personal sellers 18 Whose campaign is this? 20 Supporting the personal sellers 21 Radio script 23 The best laid plans..
    [Show full text]
  • (ITFDE) October 20-21, 2020 Introduc
    Summary of the Thirty-First Meeting of the International Task Force for Disease Eradication (ITFDE) October 20-21, 2020 The 31st Meeting of the International Task Force for Disease Eradication (ITFDE) was convened at The Carter Center in Atlanta, GA, USA on October 20-21, 2020 at 8:30am until 2:15pm each day to discuss “The Impact of the COVID-19 Pandemic on Eradication/Elimination Programs and the Way Forward.” The Task Force members are Dr. Stephen Blount, The Carter Center (Chair); Dr. Peter Figueroa, The University of the West Indies, Jamaica; Dr. Donald Hopkins, The Carter Center; Dr. Kashef Ijaz, The Carter Center; Dr. Fernando Lavadenz, The World Bank; Dr. Mwelecele Malecela, World Health Organization (WHO); Professor David Molyneux, Liverpool School of Tropical Medicine; Dr. Ana Morice, Independent Consultant; Dr. Stefan Peterson, UNICEF; Dr. David Ross, The Task Force for Global Health; Dr. William Schluter, Centers for Disease Control and Prevention (CDC); Dr. Nilanthi de Silva, University of Kelaniya, Sri Lanka/WHO Strategic and Technical Advisory Group for Neglected Tropical Diseases (STAG-NTDs); Dr. Laurence Slutsker, PATH; Dr. Jordan Tappero, Bill & Melinda Gates Foundation; and Dr. Dyann Wirth, Harvard School of Public Health. Thirteen Task Force members (Blount, Figueroa, Hopkins, Ijaz, Lavadenz, Malecela, Molyneux, Morice, Schluter, de Silva, Slutsker, Tappero, Wirth) participated in this meeting; three were represented by an alternate (Drs. Fatima Barry for Lavadenz, Robin Nandy for UNICEF, Paul Emerson for Ross). Presenters included Drs. Natasha Crowcroft, WHO/Geneva; Matthew Ferrari, The Pennsylvania State University; Deirdre Hollingsworth, University of Oxford; Jonathan King, WHO/Geneva; James V.
    [Show full text]